Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions

The failure of targeted therapy due to the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is considered a major problem in the treatment of non-small cell lung cancer (NSCLC) patients. SerpinB2, a component of the urokinase plasminogen activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Song Yi, Park, Hyen Joo, Hong, Ji-Young, Lee, Hye-Jung, Lee, Sang Kook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997607/
https://www.ncbi.nlm.nih.gov/pubmed/27558531
http://dx.doi.org/10.1038/srep32258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997607/
https://www.ncbi.nlm.nih.gov/pubmed/27558531
http://dx.doi.org/10.1038/srep32258

Ejemplares similares